Newly published research from the Harry Perkins Institute of Medical Research is the foundation stone for human trials that may lead to a better treatment for patients with chronic kidney disease.
Associate Professor Kevin Pfleger, head of Molecular Endocrinology and Pharmacology at the Perkins, says protein passing out of the kidney and into the urine is a key indicator of chronic kidney disease. He says the research outlined in the new publication will hopefully lead to a better outcome for those suffering from this condition.
A/Professor Kevin Pfleger is also Chief Scientific Advisor of Dimerix Bioscience, a drug discovery and development company that is now recruiting kidney disease patients to take part in clinical trials in Melbourne.
“We have developed patented technology here in Western Australia that identifies a particular functional interaction between two receptors in the kidney,” he says.
“One of these receptors is being targeted by a current treatment but the clinical trials at the Austin Hospital in Melbourne will tell us whether a combination of drugs is more effective in treating chronic kidney disease. Our pre-clinical research so far, in collaboration with Professor Darren Kelly at St. Vincent’s Hospital, Melbourne, has shown very positive results.”
A/Professor Pfleger says the paper, Functional Interaction between Angiotensin II Receptor Type 1 and Chemokine (C-C Motif) Receptor 2 with Implications for Chronic Kidney Disease, which has been published in the journal PLOS One, is significant at a time when chronic kidney disease is becoming an increasing health burden.
“Chronic kidney disease has been identified as the seventh most common cause of death in Australia and it is being fuelled by the rise in obesity,” he says.